Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
RLYB vs MXCT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
RLYB Captures Overall Composite Edge (63.0 BUY vs 41.7 SELL), While MXCT Leads 4–0 on Growth & Valuation Pillars
RLYB Overall Winner
6-Pillar Tally: RLYB 0 – 4 MXCT (2 Tie)
Matrix Metrics: RLYB 6 – 3 MXCT
As of Nov 20, 2026, Rallybio Corporation (RLYB) captures the overall head-to-head institutional edge over MaxCyte, Inc. (MXCT) on higher Unified Composite conviction (63.0/100 BUY vs. 41.7/100 SELL) after splitting the core matrix 6–3 (led by composite factor balance), while MXCT wins 4–0 across the 6-pillar growth and valuation breakdown. RLYB trades at $15.47 (N/M Forward P/E, -5050.9% operating margin) versus MXCT at $1.37 (N/M Forward P/E, -85.5% operating margin).
- Growth vs. Quality Trade-Off: RLYB earns the overall head-to-head edge with a stronger Unified Composite Score (63.0/100 BUY vs. MXCT 41.7/100 SELL) and 0.37β · 24% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: RLYB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About RLYB vs MXCT
RLYB
Head-to-Head Winner
Rallybio Corporation Common Stock
$15.47
-0.32% 1D
Market Cap
$86.9M
TTM Revenue
$434,000
Forward P/E
N/M
Beta / 30D Vol
0.37β · 24% Vol
Unified Composite Score
63.0
BUY
Tech 81.0
Fund 63.0
Flow 50.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
MXCT
MaxCyte, Inc. Common Stock
$1.37
+7.03% 1D
Market Cap
$132.2M
TTM Revenue
$34M
Forward P/E
N/M
Beta / 30D Vol
1.19β · 96% Vol
Unified Composite Score
41.7
SELL
Tech 46.0
Fund 52.0
Flow 62.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (RLYB 0 – 4 MXCT)
1. Valuation Multiples
Tie
Forward P/E
N/M
N/M
Trailing P/E
3.4x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
105.5x
3.9x
2. Growth & Scale
MXCT
Revenue Growth (YoY)
+0.0%
+48.7%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$434,000
$34M
Market Cap
$86.9M
$132.2M
3. Profitability & Quality
MXCT
Gross Margin
N/A
81.0%
Operating Margin
-5050.9%
-85.5%
Net Profit Margin
6177.4%
-81.4%
Return on Equity (ROE)
34.5%
-16.9%
4. Balance Sheet & Cash Flow
MXCT
Cash Generation (TTM)
-$28M
-$24M
Cash Flow Margin
N/A
-69.2%
Net Cash / Leverage
$41M Net Cash
$2.2M Net Debt (0.11x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
MXCT
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Scale & Operating Efficiency Moat
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: RLYB (6) vs MXCT (3)| Institutional Metric | RLYB | MXCT | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $86.9M | $132.2M | MXCT | |
| Trailing P/E Ratio | 3.4x | N/M | RLYB | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +0.0% | +48.7% | MXCT | |
| Operating Margin (TTM) | -5050.9% | -85.5% | MXCT | |
| Net Profit Margin | 6177.4% | -81.4% | RLYB | |
| Return on Equity (ROE) | 34.5% | -16.9% | RLYB | |
| 52-Week Range Position | 88% ($1–$18) | 63% ($1–$2) | RLYB | |
| Beta / 30D Volatility | 0.37β · 24% Vol | 1.19β · 96% Vol | RLYB | |
| Unified Institutional Score | 63.0 / 100 (BUY) | 41.7 / 100 (SELL) | RLYB | |
| Trailing 12M Revenue (USD) | $434,000 | $34M | Scale | |
| Gross Profit Margin (TTM) | N/A | 81.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 105.5x EV/Rev | N/M PEG · 3.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$28M ($41M Net Cash) | -$24M ($2.2M Net Debt (0.11x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
MXCT +1.47 pp
3M Horizon
MXCT +6.48 pp
6M Horizon
MXCT +34.31 pp
1Y Horizon
RLYB +2397.78 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RLYB Revenue | MXCT Revenue | RLYB Op. Margin | MXCT Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | N/A | $10M | N/A | -93.7% | MXCT |
| FY2020 | N/A | $20M | N/A | -71.6% | MXCT |
| FY2021 | N/A | $20M | N/A | -84.3% | MXCT |
| FY2022 | N/A | $30M | N/A | -95.2% | MXCT |
| FY2023 | N/A | $20M | N/A | -247.7% | MXCT |
| FY2024 | $0M | $20M | -9511.9% | -230.5% | MXCT |
| FY2025 | $0M | $20M | -3853.6% | -247.6% | MXCT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
RLYB
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact RLYB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
MXCT
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
RLYB Moat Profile
Scale & Operating Efficiency Moat
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
MXCT Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ RLYB vs MXCT Key Questions & Quantitative Answers
As of Nov 20, 2026, Rallybio Corporation (RLYB) captures the overall head-to-head institutional edge over MaxCyte, Inc. (MXCT) on higher Unified Composite conviction (63.0/100 BUY vs. 41.7/100 SELL) after splitting the core matrix 6–3 (led by composite factor balance), while MXCT wins 4–0 across the 6-pillar growth and valuation breakdown. RLYB trades at $15.47 (N/M Forward P/E, -5050.9% operating margin) versus MXCT at $1.37 (N/M Forward P/E, -85.5% operating margin). Growth vs. Quality Trade-Off: RLYB earns the overall head-to-head edge with a stronger Unified Composite Score (63.0/100 BUY vs. MXCT 41.7/100 SELL) and 0.37β · 24% Vol risk profile, whereas MXCT leads top-line expansion (+48.7% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: RLYB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MXCT leads the Growth & Scale pillar: RLYB posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $434,000 TTM revenue (N/A gross margin, -5050.9% operating margin), compared with MXCT at +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), RLYB cumulative revenue shifted N/A while MXCT shifted +100.0%. In operating R&D and SG&A reinvestment, RLYB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MXCT.
RLYB and MXCT trade at balanced relative valuation multiples. RLYB trades at N/M Forward P/E, 3.4x Trailing P/E, N/M PEG, and 105.5x EV/Revenue (unreported FCF margin), whereas MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RLYB (34.5% ROE) versus MXCT (-16.9% ROE) capital efficiency.
In options market volatility and institutional positioning, RLYB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.37β · 24% Vol realized risk). By comparison, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
MXCT vs RLYB · Reverse Pair
RLYB vs XLO
· Sector Peer
RLYB vs TYRA
· Sector Peer
RLYB vs LYEL
· Sector Peer
MXCT vs CTKB
· Sector Peer
MXCT vs SGHT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem